The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Drug: Ibrutinib
Ibrutinib
Inclusion Criteria:
- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.
Exclusion Criteria:
- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.
- Patients previously treated with ibrutinib are not eligible.
- Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
Phoenix, Arizona,
Duarte, California,
La Jolla, California,
Los Angeles, California,
Stanford, California,
Denver, Colorado,
Norwalk, Connecticut,
Stamford, Connecticut,
Washington, District of Columbia,
Brandon, Florida,
Miami Beach, Florida,
Ocala, Florida,
Orlando, Florida,
Palm Beach Gardens, Florida,
Atlanta, Georgia,
Chicago, Illinois,
Springfield, Illinois,
Goshen, Indiana,
Sioux City, Iowa,
Lexington, Kentucky,
Louisville, Kentucky,
Metairie, Louisiana,
Baltimore, Maryland,
Boston, Massachusetts,
Worcester, Massachusetts,
Ann Arbor, Michigan,
Detroit, Michigan,
Rochester, Minnesota,
Jefferson City, Missouri,
Saint Louis, Missouri,
Lincoln, Nebraska,
Omaha, Nebraska,
Reno, Nevada,
Hackensack, New Jersey,
New Hyde Park, New York,
New York, New York,
Syracuse, New York,
Durham, North Carolina,
Cleveland, Ohio,
Columbus, Ohio,
Hershey, Pennsylvania,
Philadelphia, Pennsylvania,
Pittsburgh, Pennsylvania,
Watertown, South Dakota,
Knoxville, Tennessee,
Nashville, Tennessee,
Austin, Texas,
Dallas, Texas,
Houston, Texas,
Lubbock, Texas,
Burlington, Vermont,
Charlottesville, Virginia,
Morgantown, West Virginia,
Madison, Wisconsin,